(ITCI) Intracellular Th - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46116X1019
ITCI: Schizophrenia, Bipolar, Depression, Parkinson's, Dementia, Pain
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a biopharmaceutical company dedicated to addressing significant medical needs in neuropsychiatric and neurological disorders. Their approach focuses on small molecule drugs targeting intracellular signaling mechanisms in the central nervous system (CNS), a strategy that holds promise for treating complex CNS conditions. The companys approved product, CAPLYTA, is used for schizophrenia and bipolar depression in adults, marking a significant milestone in their portfolio.
Their pipeline is robust, with Lumateperone in Phase 3 trials for various depressive disorders, showcasing potential for treating a range of neuropsychiatric conditions. Additionally, they are developing ITI-214 for Parkinsons disease and other CNS disorders, ITI-1284 for dementia-related neuropsychiatric issues, and ITI-333 for substance use and pain management with psychiatric comorbidities. This diverse pipeline positions the company for potential future growth in multiple therapeutic areas.
Founded in 2002 and headquartered in New York, the company has a market capitalization of approximately $1.35 billion. Financial metrics indicate a forward P/E of 119.05 and a P/S ratio of 22.13, reflecting market
Additional Sources for ITCI Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ITCI Stock Overview
| Market Cap in USD | 13,956m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-01-07 |
ITCI Stock Ratings
| Growth 5y | 96.8% |
| Fundamental | -13.1% |
| Dividend | 0.0% |
| Rel. Strength Industry | 102 |
| Analysts | 4.53/5 |
| Fair Price Momentum | 181.78 USD |
| Fair Price DCF | - |
ITCI Dividends
No Dividends PaidITCI Growth Ratios
| Growth Correlation 3m | 93.3% |
| Growth Correlation 12m | 89.5% |
| Growth Correlation 5y | 94.6% |
| CAGR 5y | 58.96% |
| CAGR/Max DD 5y | 1.66 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 94.61 |
| Beta | 0.65 |
| Volatility | 15.50% |
| Current Volume | 1909.6k |
| Average Volume 20d | 1821k |
As of March 14, 2025, the stock is trading at USD 131.36 with a total of 1,909,588 shares traded.
Over the past week, the price has changed by +0.08%, over one month by +2.58%, over three months by +58.21% and over the past year by +101.44%.
Neither. Based on ValueRay Fundamental Analyses, Intracellular Th is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -13.08 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ITCI as of March 2025 is 181.78. This means that ITCI is currently undervalued and has a potential upside of +38.38% (Margin of Safety).
Intracellular Th has received a consensus analysts rating of 4.53. Therefor, it is recommend to buy ITCI.
- Strong Buy: 9
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ITCI Intracellular Th will be worth about 201.5 in March 2026. The stock is currently trading at 131.36. This means that the stock has a potential upside of +53.43%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 132 | 0.5% |
| Analysts Target Price | 103.5 | -21.2% |
| ValueRay Target Price | 201.5 | 53.4% |